药华药(6446)今(4)日召开重大讯息记者会，宣布旗下新药P1101原发性血小板过多症(ET)全球多国多中心第三期临床试验(以下简称SURPASS ET)主要评估指标 ...

Findings showed 42.9% of P1101-treated patients achieved durable responses at both 9 and 12 months compared with 6% in those treated with anagrelide (P =.0001). Topline data were announced from a ...

In the SURPASS-ET trial, the company weighed its treatment, dubbed P1101 in the study, against platelet-reducing anagrelide as a second-line therapy for patients with essential thrombocythemia (ET).